

Group III - Claims 13, drawn to methods of screening for an antagonist or agonist of the A55 mouse polypeptide.

The Examiner further notes that claim 10 is included in both Groups I and II because it is a Markush-like claim drawn to the subject matter of both Group I (polypeptides) and Group II (antibodies).


In response, Applicants elect the claims of **Group I** (claims 1-8 and 10-12), drawn to mouse A55 polypeptides and compositions thereof, encoding cDNA, vectors, host cells and methods of making the polypeptide, **without traverse**.

II. Conclusion

In view of the above, reconsideration and allowance of this application are now believed to be in order, and such actions are hereby solicited. If any points remain in issue which the Examiner feels may be best resolved through a personal or telephone interview, the Examiner is kindly requested to contact the undersigned at the telephone number listed below.

Applicant hereby petitions for any extension of time which may be required to maintain the pendency of this case, and any required fee, except for the Issue Fee, for such extension is to be charged to Deposit Account No. 19-4880.

Respectfully submitted,



Drew Hissong
Registration No. 44,765

SUGHRUE MION, PLLC
2100 Pennsylvania Avenue, N.W.
Washington, D.C. 20037-3213
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

Date: December 13, 2001